Rigel Pharma

Q2 FY2026 EarningsQ2 FY26 significantly outperformed consensus estimates, driven by a robust top-line beat of $78.7M vs. $55.3M expected. TAVALISSE sales surged 18% YoY to $47.4M, while contract revenue was bolstered by $5.8M from Kissei milestones. GAAP EPS of $0.88 far exceeded the $0.77 expectation due to strong operating leverage and the newly acquired VEPPANU asset. Management’s mid-August launch for VEPPANU provides a clear near-term catalyst for further growth.